Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
15 Nov 2023
Historique:
received: 26 09 2023
accepted: 28 10 2023
medline: 27 11 2023
pubmed: 16 11 2023
entrez: 16 11 2023
Statut: epublish

Résumé

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and post-COVID condition can present similarities such as fatigue, brain fog, autonomic and neuropathic symptoms. The study included 87 patients with post-COVID condition, 50 patients with ME/CFS, and 50 healthy controls (HC). The hemodynamic autonomic function was evaluated using the deep breathing technique, Valsalva maneuver, and Tilt test. The presence of autonomic and sensory small fiber neuropathy (SFN) was assessed with the Sudoscan and with heat and cold evoked potentials, respectively. Finally, a complete neuropsychological evaluation was performed. The objective of this study was to analyze and compare the autonomic and neuropathic symptoms in post-COVID condition with ME/CFS, and HC, as well as, analyze the relationship of these symptoms with cognition and fatigue. Statistically significant differences were found between groups in heart rate using the Kruskal-Wallis test (H), with ME/CFS group presenting the highest (H = 18.3; p ≤ .001). The Postural Orthostatic Tachycardia Syndrome (POTS), and pathological values in palms on the Sudoscan were found in 31% and 34% of ME/CFS, and 13.8% and 19.5% of post-COVID patients, respectively. Concerning evoked potentials, statistically significant differences were found in response latency to heat stimuli between groups (H = 23.6; p ≤ .01). Latency was highest in ME/CFS, and lowest in HC. Regarding cognition, lower parasympathetic activation was associated with worse cognitive performance. Both syndromes were characterized by inappropriate tachycardia at rest, with a high percentage of patients with POTS. The prolonged latencies for heat stimuli suggested damage to unmyelinated fibers. The higher proportion of patients with pathological results for upper extremities on the Sudoscan suggested a non-length-dependent SFN.

Sections du résumé

BACKGROUND BACKGROUND
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and post-COVID condition can present similarities such as fatigue, brain fog, autonomic and neuropathic symptoms.
METHODS METHODS
The study included 87 patients with post-COVID condition, 50 patients with ME/CFS, and 50 healthy controls (HC). The hemodynamic autonomic function was evaluated using the deep breathing technique, Valsalva maneuver, and Tilt test. The presence of autonomic and sensory small fiber neuropathy (SFN) was assessed with the Sudoscan and with heat and cold evoked potentials, respectively. Finally, a complete neuropsychological evaluation was performed. The objective of this study was to analyze and compare the autonomic and neuropathic symptoms in post-COVID condition with ME/CFS, and HC, as well as, analyze the relationship of these symptoms with cognition and fatigue.
RESULTS RESULTS
Statistically significant differences were found between groups in heart rate using the Kruskal-Wallis test (H), with ME/CFS group presenting the highest (H = 18.3; p ≤ .001). The Postural Orthostatic Tachycardia Syndrome (POTS), and pathological values in palms on the Sudoscan were found in 31% and 34% of ME/CFS, and 13.8% and 19.5% of post-COVID patients, respectively. Concerning evoked potentials, statistically significant differences were found in response latency to heat stimuli between groups (H = 23.6; p ≤ .01). Latency was highest in ME/CFS, and lowest in HC. Regarding cognition, lower parasympathetic activation was associated with worse cognitive performance.
CONCLUSIONS CONCLUSIONS
Both syndromes were characterized by inappropriate tachycardia at rest, with a high percentage of patients with POTS. The prolonged latencies for heat stimuli suggested damage to unmyelinated fibers. The higher proportion of patients with pathological results for upper extremities on the Sudoscan suggested a non-length-dependent SFN.

Identifiants

pubmed: 37968647
doi: 10.1186/s12967-023-04678-3
pii: 10.1186/s12967-023-04678-3
pmc: PMC10648633
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

814

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI20/01076
Organisme : EITB maratoia
ID : BIOS21/COV/006
Organisme : Basque Government
ID : 2021111006
Organisme : Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza
ID : PRE_2022_2_0111

Informations de copyright

© 2023. The Author(s).

Références

Auton Neurosci. 2021 Nov;235:102828
pubmed: 34144933
J Vis Exp. 2011 Jul 19;(53):
pubmed: 21788940
Curr Pain Headache Rep. 2022 Jun;26(6):429-438
pubmed: 35384587
Muscle Nerve. 2014 Dec;50(6):956-61
pubmed: 24647968
J Clin Med. 2020 Aug 05;9(8):
pubmed: 32764516
Medicina (Kaunas). 2021 May 19;57(5):
pubmed: 34069603
Diabetes Technol Ther. 2013 Nov;15(11):948-53
pubmed: 23889506
Cancer. 2019 Feb 1;125(3):353-364
pubmed: 30602059
Nurse Pract. 2022 Jan 1;47(1):12-19
pubmed: 34928881
J Peripher Nerv Syst. 2019 Mar;24(1):19-33
pubmed: 30569495
Autoimmun Rev. 2022 May;21(5):103071
pubmed: 35182777
Lancet Respir Med. 2021 Feb;9(2):129
pubmed: 33453162
Mult Scler. 2020 Jan;26(1):6-16
pubmed: 31138052
Muscle Nerve. 2022 Apr;65(4):440-443
pubmed: 34766365
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Mov Disord. 2018 Nov;33(11):1712-1723
pubmed: 30264539
Nutr Metab Cardiovasc Dis. 2011 Jan;21(1):69-78
pubmed: 21247746
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Clin Auton Res. 2021 Jun;31(3):385-394
pubmed: 33860871
J Intern Med. 2019 Apr;285(4):352-366
pubmed: 30372565
Behav Brain Funct. 2011 Oct 27;7:46
pubmed: 22032726
Neurol Neuroimmunol Neuroinflamm. 2022 Mar 1;9(3):
pubmed: 35232750
Muscle Nerve. 2022 Jan;65(1):10-28
pubmed: 34374103
Naunyn Schmiedebergs Arch Pharmacol. 2023 Mar;396(3):453-468
pubmed: 36460816
J Clin Med. 2022 Jan 20;11(3):
pubmed: 35159974
Trends Mol Med. 2021 Sep;27(9):895-906
pubmed: 34175230
Front Physiol. 2013 May 16;4:113
pubmed: 23720636
BBA Adv. 2022 Oct 31;2:100061
pubmed: 37082580
Heart Rhythm. 2022 Nov;19(11):1880-1889
pubmed: 35853576
Sci Rep. 2021 Jul 7;11(1):14042
pubmed: 34234251
Clin Med (Lond). 2021 Jan;21(1):e63-e67
pubmed: 33243837
Arq Neuropsiquiatr. 2018 Mar;76(3):200-208
pubmed: 29809227
Nat Cardiovasc Res. 2022 Dec;1(12):1187-1194
pubmed: 37303827
Ugeskr Laeger. 2018 Jul 2;180(27):
pubmed: 29984698
Int Ophthalmol. 2022 Sep;42(9):2847-2854
pubmed: 35380318

Auteurs

N Azcue (N)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain.

R Del Pino (R)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain. delpinorocio@gmail.com.

M Acera (M)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain.

T Fernández-Valle (T)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, Barakaldo, Spain.
Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa, Spain.

N Ayo-Mentxakatorre (N)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain.

T Pérez-Concha (T)

Department of Neurology, Cruces University Hospital-OSAKIDETZA, Barakaldo, Spain.
Department of Medicine, School of Medicine, University of Deusto, Bilbao, Spain.

A Murueta-Goyena (A)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain.
Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa, Spain.

J V Lafuente (JV)

Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa, Spain.

A Prada (A)

Department of Immunology, Donostia University Hospital-OSAKIDETZA, San Sebastián, Spain.
Spanish Network for the Research in Multiple Sclerosis, San Sebastian, Spain.

A López de Munain (A)

Department of Neurology, Donostia University Hospital-OSAKIDETZA, San Sebastián, Spain.
Department of Neurosciences, Biodonostia Health Research Institute, San Sebastián, Spain.
Department of Neurosciences, University of the Basque Country UPV-EHU, San Sebastián, Spain.
Department of Medicine, School of Medicine, University of Deusto, Bilbao, Spain.
CIBERNED-CIBER, Institute Carlos III, Madrid, Spain.

G Ruiz Irastorza (G)

Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Department of Autoimmune Diseases, Cruces University Hospital-OSAKIDETZA, Barakaldo, Spain.

D Martín-Iglesias (D)

Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Department of Autoimmune Diseases, Cruces University Hospital-OSAKIDETZA, Barakaldo, Spain.

L Ribacoba (L)

Department of Internal Medicine, Cruces University Hospital, Barakaldo, Spain.

I Gabilondo (I)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, Barakaldo, Spain.
The Basque Foundation for Science, IKERBASQUE, Bilbao, Spain.

J C Gómez-Esteban (JC)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain. juancarlosgomezesteban@gmail.com.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, Barakaldo, Spain. juancarlosgomezesteban@gmail.com.
Department of Neurosciences, University of the Basque Country UPV/EHU, Leioa, Spain. juancarlosgomezesteban@gmail.com.
Department of Medicine, School of Medicine, University of Deusto, Bilbao, Spain. juancarlosgomezesteban@gmail.com.
CIBERNED-CIBER, Institute Carlos III, Madrid, Spain. juancarlosgomezesteban@gmail.com.

B Tijero-Merino (B)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, 48903, Barakaldo (Bizkaia), CP, Spain.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, Barakaldo, Spain.
Department of Medicine, School of Medicine, University of Deusto, Bilbao, Spain.
CIBERNED-CIBER, Institute Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH